In this map, you can see the location of PF Warrior Patients, caregivers and support Groups along with care center network locations. Learn more about pulmonary fibrosis: https://bit.ly/1lfMsiZ…
Pulmonary Fibrosis Warrior Map
Researchers from a large number of international institutions have published an integrated analysis showing that long-term treatment with pirfenidone (Esbriet, Genentech, Roche) in patients with idiopathic pulmonary fibrosis (IPF) can be considered safe. The study, “Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of…
Read the articles here: 1. Tissue Engineering Grows New Lungs in Lab That Could Revolutionize IPF Treatment 2. NY Times Covers Story of IPF Patient’s Progress with Esbriet Treatment 3. IPF Disease Carries High Economic and Healthcare Burden…
Gilead Sciences, Inc. recently announced in a press release that it is stopping its RAINIER Phase II clinical trial testing the investigational monoclonal antibody simtuzumab in patients with idiopathic pulmonary fibrosis (IPF), noting that the experimental therapy did not demonstrate efficacy in treating the disease. Simtuzumab is a humanized monoclonal…
It’s that time of year again. I take you through why I dislike New Year’s resolutions and a simple DIY to help you make the most of your 2016, especially if you’re a transplant recipient or have a chronic illness. If you would like to see more videos like…
https://www.youtube.com/watch?v=a9D2HUyud-k Learn more about Pulmonary Fibrosis: https://bit.ly/1lfMsiZ Pulmonary Fibrosis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of…
MedImmune, AstraZeneca’s biologic research and development arm, announced that it is expanding its collaboration with the University of California, San Francisco (UCSF), to focus on basic research and translational sciences into diseases involving the Respiratory, Inflammation and Autoimmunity (RIA) fields. The partnership continues joint work begun in 2014, and the two will initiate about a half-dozen research projects…
“Dr. Timothy Whelan, Medical Director of the Lung Transplant Program from the Medical University of South Carolina, provides advice for two new drugs, Pirfenidone and Nintedanib, to slow the progression of IPF.” Read more about IPF and approved therapies: https://bit.ly/1lfMsiZ…
“I’ve experienced no change in my condition, no major deterioration since I started on Esbriet,” said Daniel Castner in an interview with The New York Times. Castner happily added that he’s been free from any treatment side effects, too. Read the top-7 #esbriet articles here: https://wp.me/p56x0V-1kZ Castner, of Napa, California, told Jane…
1. Genentech’s PF Drug Esbriet Shown To Lower Mortality Rates in New Study Read the article here: https://bit.ly/1URSd1G 2. Esbriet’s Promise and Potential as a PF Therapy Read the article here: https://bit.ly/1kub6MJ 3. Phase III Trials…
